Cullinan Oncology LLC (CGEM) — Cash Flow-to-Debt Ratio
Cullinan Oncology LLC (CGEM) has a Cash Flow-to-Debt Ratio of -1.25x as of March 2026, meaning its operating cash flow of $-46.05 Million could theoretically repay -1% of its total liabilities ($36.81 Million) in one year. Explore CGEM long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cullinan Oncology LLC Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Cullinan Oncology LLC across 12 annual periods. Also explore balance sheet size of Cullinan Oncology LLC for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cullinan Oncology LLC (2013–2025)
Year-by-year debt coverage analysis for Cullinan Oncology LLC. For market capitalisation and broader financial context, see Cullinan Oncology LLC (CGEM) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.43x | $-175.75 Million | $39.64 Million | ▲ +3.9% |
| 2024 | -4.61x | $-145.30 Million | $31.50 Million | ▼ -4.1% |
| 2023 | -4.43x | $-134.28 Million | $30.29 Million | ▲ +8.7% |
| 2022 | -4.86x | $-126.66 Million | $26.09 Million | ▼ -32.0% |
| 2021 | -3.68x | $-43.43 Million | $11.81 Million | ▼ -77.8% |
| 2020 | -2.07x | $-29.77 Million | $14.39 Million | ▼ -1289.4% |
| 2019 | -0.15x | $-20.90 Million | $140.37 Million | ▲ +39.2% |
| 2018 | -0.25x | $-13.55 Million | $55.29 Million | ▲ +38.1% |
| 2016 | -0.40x | $-228.91K | $578.28K | ▼ -1950.7% |
| 2015 | -0.02x | $-24.03K | $1.24 Million | ▲ +75.8% |
| 2014 | -0.08x | $-91.72K | $1.15 Million | ▲ +88.6% |
| 2013 | -0.70x | $-718.41K | $1.03 Million | — |